Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

CAPOOR, M. N., F. S. AHMED, A. MCDOWELL a Ondřej SLABÝ. Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2? FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY. LAUSANNE: FRONTIERS MEDIA SA, 2020, roč. 10, DEC 2020, s. 1-5. ISSN 2235-2988. Dostupné z: https://dx.doi.org/10.3389/fcimb.2020.605334.

Základní údaje

Originální název

Is the "Common Cold" Our Greatest Ally in the Battle Against SARS-CoV-2?

Autoři

CAPOOR, M. N. (garant), F. S. AHMED, A. MCDOWELL a Ondřej SLABÝ (203 Česká republika, domácí)

Vydání

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, LAUSANNE, FRONTIERS MEDIA SA, 2020, 2235-2988

---

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.293

Kód RIV

RIV/00216224:14110/20:00118278

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3389/fcimb.2020.605334

UT WoS

000603982400001

Klíčová slova anglicky

SARS-CoV-2; COVID-19; T-cell; human coronaviruses; immunity; contact tracing; children

Štítky

14110513, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

---

Anotace

V originále

The discovery of T-cell responses to SARS-CoV-2 in non-infected individuals indicates cross-reactive immune memory from prior exposure to human coronaviruses (HCoV) that cause the common cold. This raises the possibility that "immunity" could exist within populations at rates that may be higher than serology studies estimate. Besides specialized research labs, however, there is limited ability to measure HCoV CD4+ and CD8+ T-cell responses to SARS-CoV-2 infection, which currently impedes interpretation of any potential correlation between COVID-19 disease pathogenesis and the calibration of pandemic control measures. Given this limited testing ability, an alternative approach would be to exploit the large cohort of currently available data from which statistically significant associations may be generated. This would necessitate the merging of several public databases including patient and contact tracing, which could be created by relevant public health organizations. Including data from both symptomatic and asymptomatic patients in SARS-CoV-2 databases and surveillance systems could provide the necessary information to allow for more informed decisions.